- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | Biogen pays Stoke $165M, bagging Dravet prospect to fire up late-phase pipeline | ||
| Di | Gilead loses interest in Arcus' kidney cancer rival to Merck's Welireg | ||
| Di | Solid Bio's stock soars as early DMD gene therapy data beat expectations | ||
| Di | Basilea opts not to take MRSA antibiotic into clinic due to 'stringent risk-return criteria' | ||
| 14.02. | ARPA-H director removed by Trump administration | ||
| 14.02. | Cell death biotech Kojin winds down, citing 4 funding challenges | ||
| 14.02. | Volta Medical's afib AI shows gains in cardiac ablation study | ||
| 14.02. | Allogene's phase 1 lymphoma data show CAR-T could 'leapfrog' competition: analysts | ||
| 14.02. | Boston biotech Bambusa banks $90M for next-gen bispecifics | ||
| 14.02. | Corbus posts first US data on challenger to Pfizer's ADC Padcev | ||
| 14.02. | Moderna's norovirus vaccine trial placed on FDA hold over reported case of Guillain-Barré syndrome | ||
| 14.02. | Otsuka breaks up with cancer candidates on strategic grounds | ||
| 13.02. | Genentech archives diversity reports amid site update, examines 'potential implications of executive orders' | ||
| 13.02. | Conduit taps Charles River to build preclinical autoimmune case for AstraZeneca diabetes asset | ||
| 13.02. | After AI antibodies and peptides, UW's Baker Lab now tackles computer-generated enzymes | ||
| 13.02. | Encoded lays off 29% of staff to fund Dravet syndrome gene therapy trial | ||
| 13.02. | Amgen ends Ideaya cancer combination trial after partner unveils rival molecule | ||
| 13.02. | Aardvark Therapeutics heads to Nasdaq with $94M IPO to fund more appetite-suppressant trials | ||
| 13.02. | Galapagos drops one CD19 CAR-T to focus on 'flagship' program | ||
| 13.02. | Sanofi takes $250M hit after gamble on J&J E. coli vaccine ends in phase 3 failure | ||
| 12.02. | Michigan CRO buys Exploristics for its cloud-based modeling platform | ||
| 12.02. | Oligonucleotide stops gene expansion process that drives Huntington's disease: study | ||
| 12.02. | UK court rules against Abbott in diabetes CGM trademark case versus Sinocare | ||
| 12.02. | AnaptysBio's PD-1 drug reduces rheumatoid arthritis in phase 2 trial | ||
| 12.02. | Judge puts nationwide hold on NIH grant change after universities sue |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
